BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38490765)

  • 21. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA).
    Brown AL; Hahn CN; Scott HS
    Blood; 2020 Jul; 136(1):24-35. PubMed ID: 32430494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
    Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
    Pathol Oncol Res; 2018 Jan; 24(1):83-88. PubMed ID: 28357685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms.
    Sullivan MJ; Palmer EL; Botero JP
    Curr Hematol Malig Rep; 2022 Oct; 17(5):105-112. PubMed ID: 35751752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].
    Király PA; Kállay K; Marosvári D; Benyó G; Szőke A; Csomor J; Bödör C
    Orv Hetil; 2016 Feb; 157(8):283-9. PubMed ID: 26876264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline and somatic drivers in inherited hematologic malignancies.
    Zoller J; Trajanova D; Feurstein S
    Front Oncol; 2023; 13():1205855. PubMed ID: 37904876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genomic aberrations in myelodysplastic syndromes and related disorders].
    Makishima H
    Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
    Davidsson J; Puschmann A; Tedgård U; Bryder D; Nilsson L; Cammenga J
    Leukemia; 2018 May; 32(5):1106-1115. PubMed ID: 29535429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Predisposition to Hematolymphoid Neoplasia.
    Weinberg OK; Kuo F; Calvo KR
    Am J Clin Pathol; 2019 Aug; 152(3):258-276. PubMed ID: 31309983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).
    Clark A; Thomas S; Hamblin A; Talley P; Kulasekararaj A; Grinfeld J; Speight B; Snape K; McVeigh TP; Snowden JA
    Br J Haematol; 2023 Apr; 201(1):35-44. PubMed ID: 36786081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.
    Hofmann I; Avagyan S; Stetson A; Guo D; Al-Sayegh H; London WB; Lehmann L
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1124-1130. PubMed ID: 32088370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells.
    Thomas ME; Abdelhamed S; Hiltenbrand R; Schwartz JR; Sakurada SM; Walsh M; Song G; Ma J; Pruett-Miller SM; Klco JM
    Leukemia; 2021 Nov; 35(11):3232-3244. PubMed ID: 33731850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation.
    Rajput RV; Arnold DE
    Curr Hematol Malig Rep; 2023 Aug; 18(4):89-97. PubMed ID: 37247092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7.
    Yoshida M; Tanase-Nakao K; Shima H; Shirai R; Yoshida K; Osumi T; Deguchi T; Mori M; Arakawa Y; Takagi M; Miyamura T; Sakaguchi K; Toyoda H; Ishida H; Sakata N; Imamura T; Kawahara Y; Morimoto A; Koike T; Yagasaki H; Ito S; Tomizawa D; Kiyokawa N; Narumi S; Kato M
    Br J Haematol; 2020 Dec; 191(5):835-843. PubMed ID: 32770553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in germline predisposition to acute leukaemias and myeloid neoplasms.
    Klco JM; Mullighan CG
    Nat Rev Cancer; 2021 Feb; 21(2):122-137. PubMed ID: 33328584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
    Martin ES; Ferrer A; Mangaonkar AA; Khan SP; Kohorst MA; Joshi AY; Hogan WJ; Olteanu H; Moyer AM; Al-Kali A; Tefferi A; Chen D; Wudhikarn K; Go R; Viswanatha D; He R; Ketterling R; Nguyen PL; Oliveira JL; Gangat N; Lasho T; Patnaik MM
    Am J Hematol; 2021 Nov; 96(11):1450-1460. PubMed ID: 34390506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
    Miller LH; Qu CK; Pauly M
    Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid malignancies: mutations, models and management.
    Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
    BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and molecular correlates of somatic and germline
    Badar T; Nanaa A; Foran JM; Viswanatha D; Al-Kali A; Lasho T; Finke C; Alkhateeb HB; He R; Gangat N; Shah M; Tefferi A; Mangaonkar AA; Litzow MR; Ongie LJ; Chlon T; Ferrer A; Patnaik MM
    Haematologica; 2023 Nov; 108(11):3033-3043. PubMed ID: 37199125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
    Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
    Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.